CITRYLL
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
CITRYLL
Social Links:
Industry:
Biopharma Biotechnology Medical Medical Device Neuroscience
Founded:
2015-01-01
Address:
Oss, Noord-Brabant, The Netherlands
Country:
The Netherlands
Website Url:
http://www.citryll.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
20.79 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Euro WordPress 6.0 WPForms
Similar Organizations
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
Seventure Partners
Seventure Partners investment in Series B - Citryll
BrightGene
BrightGene investment in Series B - Citryll
BOM
BOM investment in Series B - Citryll
BioGeneration Ventures
BioGeneration Ventures investment in Series B - Citryll
ModiQuest B.V.
ModiQuest B.V. investment in Series B - Citryll
Curie Capital
Curie Capital investment in Series A - Citryll
BrightGene
BrightGene investment in Series A - Citryll
ModiQuest B.V.
ModiQuest B.V. investment in Series A - Citryll
BOM Brabant Ventures
BOM Brabant Ventures investment in Series A - Citryll
Official Site Inspections
http://www.citryll.com Semrush global rank: 4.9 M Semrush visits lastest month: 1.78 K
- Host name: 185-151-30-223.ptr4.stackcp.net
- IP address: 185.151.30.223
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London

More informations about "Citryll"
Citryll - Crunchbase Company Profile & Funding
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers โฆSee details»
About Citryll - Citryll
About Citryll Targeting NETs, transforming inflammatory disease outcomes Citryll is pioneering an innovative approach to immune mediated inflammatory diseases. Targeting NETs as a โฆSee details»
Citryll - Funding, Financials, Valuation & Investors - Crunchbase
Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. ...See details»
Citryll BV - Drug pipelines, Patents, Clinical trials - Synapse
Explore Citryll BV with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 12 news, and 1 literature, Disease Domain:Immune System Diseases, Technology โฆSee details»
Citryll | Forbion
Citryll is developing a first-in-class therapeutic antibody targeting NETosis, a disease pathology associated with a number of inflammatory diseases. Industry Biotech citryll.com Building RK โฆSee details»
Dutch biotech startup Citryll raises โฌ85m Series B to advance its โฆ
Dec 10, 2024 The funding round was co-led by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation โ JJDC, Inc.), Forbion and โฆSee details»
Dutch biotech firm Citryll raises โฌ85m โ Euro Financial Review
Dec 9, 2024 โThe funding round was co-led by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation โ JJDC, Inc.), Forbion and โฆSee details»
Citryll announces appointments of Eduardo Bravo as CEO and Tim โฆ
With the addition of these industry experts with strong track records, we have composed a leadership team that is well-positioned to successfully reach the next stage of clinical and โฆSee details»
Citryll - Products, Competitors, Financials, Employees, โฆ
Citryll is a biotech company focused on developing therapeutics for immune-mediated inflammatory diseases. Use the CB Insights Platform to explore Citryll's full profile. Citryll - โฆSee details»
Citryll | BioGeneration Ventures
Citryll is developing a first-in-class therapeutic antibody targeting NETosis, a disease pathology associated with a number of inflammatory diseases. Year 2020 Field Immunology Status โฆSee details»
Citryll raises 85 million euros | The Pharmaletter
Dec 9, 2024 The funding round was co-led by Johnson & Johnson (NYSE: JNJ), through its corporate venture capital organization, Johnson & Johnson Innovation โ JJDC, Forbion and โฆSee details»
Dutch Biotech Citryll Secures โฌ85M Funding from J&J and Novartis โฆ
Dec 10, 2024 Citryll, a Dutch biotech company, has raised โฌ85 million in a Series B funding round co-led by Johnson & Johnson Innovation โ JJDC, Inc., Forbion, and Novartis Venture โฆSee details»
Citryll Raises EUR 85 Million Series B to Advance Novel NET
Dec 9, 2024 Citryll is developing the first NET-targeting therapy, and potentially creating a new class of therapeutics with broad applications across immune-mediated inflammatory diseases. โฆSee details»
Lonza, Citryll Enter Manufacturing Partnership โ Contract Pharma
Sep 10, 2019 The Netherlands-based biotech Citryll and contract development and manufacturing organization (CDMO) Lonza have entered a partnership to develop and โฆSee details»
CIT-013 - Drug Targets, Indications, Patents - Synapse - Patsnap
The funding round was co-led by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation โ JJDC, Inc.), Forbion and Novartis Venture โฆSee details»
Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 โฆ
Oss, Netherlands โ 20 February 2025 โ Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil โฆSee details»
Citryll Announces Dosing of the First Healthy Volunteer in a
Aug 17, 2021 OSS, The Netherlands--(BUSINESS WIRE)-- Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the โฆSee details»
Hidradenitis Suppurativa - Citryll
Hidradenitis Suppurativa Hidradenitis Suppurativa severely affects the lives of millions of patients Citryll is currently planning a Phase 2a trial of CIT-013 in Hidradenitis Suppurativa (HS).HS is โฆSee details»
Citryll annonce lโachèvement du recrutement des patients et du โฆ
Jul 31, 2024 Citryll, une société de biotechnologie au stade clinique qui développe des traitements de premier ordre pour traiter les maladies inflammatoires à médiation immunitaire, โฆSee details»